Combination of c-Met inhibitor with antibody molecule to PD-1 and uses thereof

C:\Interwove\NRPortb\DCC\SXD\19865606_l.doc-13/02/2020 The present invention relates to a pharmaceutical combination which comprises (a) at least one antibody molecule (e.g., humanized antibody molecules) that bind to Programmed Death 1 (PD-1) , and (b) at least one c-Met receptor tyrosine kinase inhibitor 5 or pharmaceutically acceptable salt thereof, for simultaneous, separate or sequential administration for the treatment of a proliferative disease, particularly a c-Met dependent proliferative disease; a pharmaceutical composition comprising such combination; a method of treating a subject having a proliferative disease comprising administration of said combination to a subject in need thereof; use of such combination for the treatment of 10 proliferative disease; and a commercial package comprising such combination. UHcI2 HH Mn M > M N& ~~P:4 H4 H H4 O 4 E4 E4 1 co a M M >D > m9( UU)U)C 0, 00F >> coc > > Fl Fl rm FZ P P 4 04 Ei 2' 0 U)U 00M M > > 00 U)U > HH> H m~ ~ oY M M p Cf Q 00 U)U< - O I-HI-H 00O 00e HH< B U)>>